Your browser doesn't support javascript.
loading
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Ji, Linong; Dong, Xiaolin; Li, Yiming; Li, Yufeng; Lim, Soo; Liu, Ming; Ning, Zu; Rasmussen, Søren; Skjøth, Trine Vang; Yuan, Guoyue; Eliaschewitz, Freddy G.
Afiliación
  • Ji L; Peking University People's Hospital No. 11, Beijing, China.
  • Dong X; Jinan Central Hospital, Affiliated to Shandong University No. 105, Jinan, China.
  • Li Y; Shanghai Huashan Hospital, Affiliated to Fudan University No. 12, Shanghai, China.
  • Li Y; Beijing Pinggu Hospital No. 59, Beijing, China.
  • Lim S; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Liu M; General Hospital of Tianjin Medical University No. 154, Tianjin, China.
  • Ning Z; Novo Nordisk (China) Pharmaceuticals Co., Ltd, Beijing, China.
  • Rasmussen S; Novo Nordisk A/S, Søborg, Denmark.
  • Skjøth TV; Novo Nordisk A/S, Søborg, Denmark.
  • Yuan G; The Affiliated Hospital of Jiangsu University No. 438, Zhenjiang, China.
  • Eliaschewitz FG; CPClin/DASA Centro de Pesquisas Clínicas, São Paulo, Brazil.
Diabetes Obes Metab ; 23(2): 404-414, 2021 02.
Article en En | MEDLINE | ID: mdl-33074557

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Metformina Tipo de estudio: Clinical_trials Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Metformina Tipo de estudio: Clinical_trials Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2021 Tipo del documento: Article País de afiliación: China